Kuemen Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.11 M
- Company Age 33 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 21.14%
- Profit Growth -19.34%
- Ebitda 53.49%
- Net Worth 48.83%
- Total Assets 49.24%
About Kuemen Laboratories
Kuemen Laboratories Private Limited (KLPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 20 June 1991 and has a history of 33 years and eight months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.11 M, as per Ministry of Corporate Affairs (MCA) records.
Madhu Goyal and Pawan Goyal serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74899DL1991PTC044697
- Company No.
044697
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jun 1991
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Kuemen Laboratories Private Limited offer?
Kuemen Laboratories Private Limited offers a wide range of products and services, including Nutritional Supplements, L-Arginine Tablet, Pharmaceutical Syrup, Dry Syrups.
Who are the key members and board of directors at Kuemen Laboratories?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madhu Goyal  | Director | 20-Jun-1991 | Current |
| Pawan Goyal | Director | 20-Jun-1991 | Current |
Financial Performance of Kuemen Laboratories.
Kuemen Laboratories Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 21.14% increase. The company also saw a substantial fall in profitability, with a 19.34% decrease in profit. The company's net worth Soared by an impressive increase of 48.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kuemen Laboratories?
In 2022, Kuemen Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kuemen Laboratories?
Kuemen Laboratories has a workforce of 9 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kuemen Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kuemen Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
